No AdComm Puts Sarepta On Path To Blockbuster Success With Duchenne Gene Therapy
Noises From US FDA Positive Ahead Of PDUFA
The US FDA’s waiving of an advisory committee is another promising signal that Sarepta's Duchenne gene therapy SRP-9001 could be approved on 29 May and set it up to become a bigger earner than Novartis’s Zolgensma.
